Affordable Access

Access to the full text

Effectiveness and safety of Yufeng Ningxin for the treatment of essential hypertension

Authors
  • Huang, Mingyan1, 2, 3
  • Long, Linzi1, 4
  • Deng, Mi1, 3
  • Yu, Zikai1, 3
  • Qu, Hua1, 3
  • Tan, Ling1, 3
  • Peng, Yuxuan1, 2, 3
  • Fu, Changgeng1, 3
  • 1 Xiyuan Hospital of China Academy of Chinese Medical Sciences
  • 2 Beijing University of Chinese Medicine, Beijing
  • 3 National Clinical Research Center for Cardiovascular Diseases of Traditional Chinese Medicine, Beijing, China.
  • 4 Fujian University of Traditional Chinese Medicine, Fuzhou
Type
Published Article
Journal
Medicine
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Mar 05, 2021
Volume
100
Issue
9
Identifiers
DOI: 10.1097/MD.0000000000024858
PMID: 33655947
PMCID: PMC7939146
Source
PubMed Central
Keywords
License
Green

Abstract

Background: Essential hypertension is the primary cause of death and disability and it has become a major public health problem globally. Yufeng Ningxin (YFNX) is a commonly used Chinese patent medicine in treating essential hypertension. The objective of this protocol is to evaluate the effectiveness and safety of YFNX for the treatment of essential hypertension. Methods: Randomized controlled trials (RCTs) in relation to the effectiveness and safety of YFNX in the treatment of essential hypertension will be systematically searched and collected from the following databases: PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang Database, Chinese Biomedical Literature Database, and Chinese Scientific Journal Database from the database inception to January 1, 2021. The data screening and extraction will be carried out by 2 different reviewers. The quality of randomized controlled trials will be assessed based on the version 2 of the risk-of-bias tool for randomized trials (RoB 2) in the Cochrane Handbook. The reduction of systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be served as the primary outcome. The secondary outcomes will include average SBP and average DBP during the day and the night measured by 24 hours ambulatory blood pressure monitoring, the clinical effectiveness rate, scores of traditional Chinese medicine syndrome, clinical symptoms, the quality of life and adverse events. Statistical analysis will be conducted with Review Manager 5.3 and STATA 14.0 software. Conclusion: This systematic review will provide strong evidence to assess the effectiveness and safety of YFNX in the treatment of essential hypertension. Trial registration number: INPLASY202110059.

Report this publication

Statistics

Seen <100 times